Where to find shrooms in florida

Psilera Bioscience researches whether there are healing properties in psychedelics, which trigger hallucinations and intensified feelings. Some scientists believe its ingredients — DMT, psilocybin and psilocin — may alleviate conditions that plague millions of Americans. We now have the tools to see how the drugs function in the brain, and analyze if they're actually working.

For local stories that matter, subscribe today. The unconventional research caught the eye of Iter Investments, an month-old Fort Lauderdale venture capital firm. Managing partner Dustin Robinson said its portfolio boasts seven psychedelics-focused companies.

Most operate outside U. Baird Inc. Previous coverage: Oregon spearheading drug decriminalization: Here's what you need to know. That includes creating analogs, slightly altered psychoactive compounds the startup formulates to see if they can treat nervous system disorders.

Since its inception in , Psilera has also worked with computational chemistry — a mixture of computer models and functional MRIs — to simulate how those compounds prompt molecular changes. Its focus has now shifted to developing delivery systems for getting the psychoactive compounds into patients, with five full-time employees and a gaggle of interns dedicated to the task.

The team is in the midst of formulating a nasal gel that would eliminate the use of needles, which have a negative association with drug abuse. It's probably wise, Witowski said, to remove sharp objects during treatment. Drugs would flow through the skin and to the brain gradually in low doses. The slow process could subdue the psychedelic effects, allowing patients to shorten or forgo experiencing a "trip," or an hours-long sensory episode.

Good trips elicit euphoria and a sense of connection to others. But bad trips can cause mental confusion, anxiety and psychotic episodes that cause people to see bizarre images or experience severe paranoia. This change could potentially relieve triggers and trauma. Other companies are implementing psychedelics to treat traumatic brain injury or to improve emotional well-being. Multiple clinical trials exploring therapeutic uses of psilocybin are underway with approval from the Food and Drug Administration.

It could aid those with common PTSD symptoms such as nightmares or unwanted memories of the trauma, the May study found. The federal government labels psychedelics as Schedule 1 drugs, meaning they may not be prescribed or used clinically. Like heroin, peyote and LSD, the drugs have a high potential for abuse and no approved medical application, the government says. A stain also fell over psychedelics in the s, when recreational use overshadowed its medicinal potential.

The Drug Enforcement Administration has granted a handful of universities permission to research psychedelics. Its co-founders — Witowski and Jackie von Salm — completed their doctoral degrees in natural products chemistry from USF.

In the past two decades, his brother cycled through almost every available anti-depressant. The majority of Americans know someone who faces similar burdens.

One in five people in the U. To Witowski, the research offers a path to explore medicinal possibilities for ailments that have proven hard — and even impossible — to solve.

Correction: An earlier version of this story incorrectly stated the number of patients Psilera plans to include its in clinical trial. Subscribe Manage my subscription Activate my subscription Log in Log out. Regions Tampa St. Letters to the Editor Submit a Letter. Investigations Narratives Pulitzer Winners. Connect with us. Contact: Joshua Ceballos. Follow: Twitter: JoshCeb. Instagram: joshceb. Don't Miss Out. Join Today. Sign Up. I Support Learn More. Latest Stories.

More ». Sign Up Now No Thanks. Become a member and go ad-free! Support Our Journalism. Privacy Policy. This Week's Issue.